Brown, J. W. L., Cunniffe, N. G., Prados, F., Kanber, B., Jones, J. L., Needham, E., . . . Coles, A. J. (2021). Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): A randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet neurology, 20(9), 709-720. https://doi.org/10.1016/S1474-4422(21)00179-4
Citácia podle Chicago (17th ed.)Brown, J William L., et al. "Safety and Efficacy of Bexarotene in Patients with Relapsing-remitting Multiple Sclerosis (CCMR One): A Randomised, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study." Lancet Neurology 20, no. 9 (2021): 709-720. https://doi.org/10.1016/S1474-4422(21)00179-4.
Citácia podľa MLA (8th ed.)Brown, J William L., et al. "Safety and Efficacy of Bexarotene in Patients with Relapsing-remitting Multiple Sclerosis (CCMR One): A Randomised, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study." Lancet Neurology, vol. 20, no. 9, 2021, pp. 709-720, https://doi.org/10.1016/S1474-4422(21)00179-4.